{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Retinal+Disease&page=37",
    "query": {
      "condition": "Retinal Disease",
      "page": 37
    },
    "page_size": 10
  },
  "pagination": {
    "page": 37,
    "page_size": 10,
    "total_count": 1618,
    "total_pages": 162,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Retinal+Disease&page=38&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Retinal+Disease&page=36&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-26T08:37:48.450Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05536401",
      "title": "P200TE Agreement and Precision Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Retina Disease",
        "Glaucoma",
        "Normal"
      ],
      "interventions": [
        {
          "name": "P200TE",
          "type": "DEVICE"
        },
        {
          "name": "Predicate Device",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Optos, PLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2022-09-02",
      "completion_date": "2022-09-20",
      "has_results": false,
      "last_update_posted_date": "2022-11-17",
      "last_synced_at": "2026-10-26T08:37:48.450Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05536401"
    },
    {
      "nct_id": "NCT01990677",
      "title": "Eplerenone for the Treatment of Central Serous Chorioretinopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Central Serous Chorioretinopathy"
      ],
      "interventions": [
        {
          "name": "25mg Eplerenone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wills Eye",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 108,
      "start_date": "2013-10",
      "completion_date": "2015-05",
      "has_results": true,
      "last_update_posted_date": "2018-11-07",
      "last_synced_at": "2026-10-26T08:37:48.450Z",
      "location_count": 10,
      "location_summary": "Cherry Hill, New Jersey • Marlton, New Jersey • Mays Landing, New Jersey + 7 more",
      "locations": [
        {
          "city": "Cherry Hill",
          "state": "New Jersey"
        },
        {
          "city": "Marlton",
          "state": "New Jersey"
        },
        {
          "city": "Mays Landing",
          "state": "New Jersey"
        },
        {
          "city": "Bala-Cynwyd",
          "state": "Pennsylvania"
        },
        {
          "city": "Bethlehem",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01990677"
    },
    {
      "nct_id": "NCT07105228",
      "title": "Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Retinal Vasculitis"
      ],
      "interventions": [
        {
          "name": "aflibercept 2mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 290000,
      "start_date": "2025-07-15",
      "completion_date": "2025-09-15",
      "has_results": false,
      "last_update_posted_date": "2025-10-10",
      "last_synced_at": "2026-10-26T08:37:48.450Z",
      "location_count": 1,
      "location_summary": "Tarrytown, New York",
      "locations": [
        {
          "city": "Tarrytown",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07105228"
    },
    {
      "nct_id": "NCT07425106",
      "title": "Comparative Study of High Performance Low-Cost Optical Coherence Tomography (Stage 1B, 2 and 3)",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Optical Coherence Tomography of Retina",
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "retinal imaging with low-cost OCT-a/LCI device",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 82,
      "start_date": "2026-02-13",
      "completion_date": "2027-02",
      "has_results": false,
      "last_update_posted_date": "2026-02-25",
      "last_synced_at": "2026-10-26T08:37:48.450Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07425106"
    },
    {
      "nct_id": "NCT07330674",
      "title": "A Phase 1 Study of ABF-101 in Single- and Multiple-Ascending Doses",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Age Related Macular Degeneration (ARMD)",
        "AMD - Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "ABF-101",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aptabio Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 68,
      "start_date": "2026-02",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-02-06",
      "last_synced_at": "2026-10-26T08:37:48.450Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07330674"
    },
    {
      "nct_id": "NCT00605943",
      "title": "Detection of Neutralizing Antibodies in Patients Treated With Bevacizumab or Ranibizumab",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Macular Degeneration"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Eye Institute (NEI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2008-01-16",
      "completion_date": "2009-08-04",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-10-26T08:37:48.450Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00605943"
    },
    {
      "nct_id": "NCT01782989",
      "title": "Clinical Study to Evaluate Treatment With ORACEA® for Geographic Atrophy (TOGA)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Geographic Atrophy"
      ],
      "interventions": [
        {
          "name": "ORACEA®",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Paul Yates, MD, PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 286,
      "start_date": "2013-02",
      "completion_date": "2020-11",
      "has_results": false,
      "last_update_posted_date": "2022-11-04",
      "last_synced_at": "2026-10-26T08:37:48.450Z",
      "location_count": 37,
      "location_summary": "Glendale, California • Poway, California • Golden, Colorado + 31 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Poway",
          "state": "California"
        },
        {
          "city": "Golden",
          "state": "Colorado"
        },
        {
          "city": "Louisville",
          "state": "Colorado"
        },
        {
          "city": "Hamden",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01782989"
    },
    {
      "nct_id": "NCT00002016",
      "title": "A Phase I/II Trial to Assess the Safety and Tolerance of Escalating Doses of a Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Retinitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cytomegalovirus Retinitis",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Sevirumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sandoz",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-10-26T08:37:48.450Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Galveston, Texas",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Galveston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002016"
    },
    {
      "nct_id": "NCT02286089",
      "title": "Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "OpRegen",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2015-04-01",
      "completion_date": "2031-01-31",
      "has_results": true,
      "last_update_posted_date": "2026-10-23",
      "last_synced_at": "2026-10-26T08:37:48.450Z",
      "location_count": 3,
      "location_summary": "San Francisco, California • Cincinnati, Ohio • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02286089"
    },
    {
      "nct_id": "NCT05409235",
      "title": "Nesvategrast (OTT166) in Diabetic Retinopathy (DR)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Retinopathy"
      ],
      "interventions": [
        {
          "name": "OTT166",
          "type": "DRUG"
        },
        {
          "name": "Vehicle control",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OcuTerra Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 225,
      "start_date": "2022-07-29",
      "completion_date": "2023-12-29",
      "has_results": true,
      "last_update_posted_date": "2024-08-09",
      "last_synced_at": "2026-10-26T08:37:48.450Z",
      "location_count": 67,
      "location_summary": "Peoria, Arizona • Phoenix, Arizona • Beverly Hills, California + 59 more",
      "locations": [
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05409235"
    }
  ]
}